Evidence map›Paper›PMID 40372859›Full record

ArticleIEEE transactions on bio-medical engineering2025

Single Treatment Boiling Histotripsy Focused Ultrasound Ablation Neither Negates nor Enhances the Activity of α-CD40 in a Pancreatic Cancer Model.

Mariia Stepanechko, Awndre Gamache, Frederic Padilla, Madison Nemshick, Lydia Kitelinger, Claire Conarroe, Matthew DeWitt, John A Hossack, Timothy N J Bullock

Abstract read
In one paragraph

Article in IEEE transactions on bio-medical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mariia Stepanechko
Awndre Gamache
Frederic Padilla
Madison Nemshick
Lydia Kitelinger
Claire Conarroe
Matthew DeWitt
John A Hossack
Timothy N J Bullock

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
VisualSonics Vevo 2100 Small Animal Ultrasound Imaging System and AccessoriesS10RR027333 · NCRR · UNIVERSITY OF VIRGINIA · PI HOSSACK, JOHN A · 2010 to 2010
$482k
NCI NIH HHS P30 CA044579NCI NIH HHS T32 CA009109NCRR NIH HHS S10 RR027333NIAID NIH HHS T32 AI007496
6 · The paper itself

Abstract

objectivePancreatic adenocarcinoma (PDAC) tumors are often unresectable and do not respond to standard anti-cancer treatments. Boiling histotripsy (BH) is a mechanical focused ultrasound ablation regimen that can target non-operable tumors. BH is a non-invasive procedure that might synergize with immunotherapies being developed for PDAC. We reasoned that BH-mediated release of tumor antigen and damage-associated molecular patterns would augment tumor immunity and cooperate with α-CD40 therapy.

methodsWe explored the efficacy of BH ablation either as monotherapy for PDAC or in combination with systemically administered α-CD40 agonistic antibodies in controlling tumor outgrowth. We further assessed the changes in the tumor immune compartment and the ability of BH to release tumor antigens by flow cytometry.

resultsA single BH treatment could not control tumor growth and had limited independent immunostimulatory properties. BH effectively liberated tumor antigen into the tumor microenvironment for acquisition by local phagocytes but did not promote its presence in the tumor-draining lymph nodes. BH did not activate either tumor- or lymph node-resident conventional dendritic cells. BH did not impede the ability of α-CD40 immunotherapy to reduce the tumor burden and promote the infiltration of M1-like macrophages and IFN-γ

conclusionOur findings indicate that PDAC tumor progression cannot be halted by BH ablation using sub-total ablation, and that the BH treatment regimen utilized in this study has limited immunogenicity. SIGNIFICANCE: Our discoveries attest to the need for optimizing BH ablation protocols to unlock its anti-tumor potential.

Indexed as

CD40 AntigensHigh-Intensity Focused Ultrasound AblationPancreatic NeoplasmsAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansImmunotherapyMiceMice, Inbred C57BLCD40 Antigens

Identifiers

PMID40372859
PMCPMC12779120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.